Midterm response with latanoprost therapy in german ocular hypertension patients

Current Eye Research

Volumn 32, Issue 1, 2007, Pages 51-56

  Thelen, Ulrich ^a   Christ, Thomas ^a   Schnober, Dietmar ^a   Hofstetter, Hans Joachim ^a   Stewart, William C ^b  

^a Pharmaceutical Research Network LLC ^*

^b University of South Carolina   (United States)

Author keywords

Germany; Latanoprost; Ocular hypertension

Indexed keywords

LATANOPROST;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GERMANY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY DYSFUNCTION;

EID: 33847032090     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680601077053     Document Type: Article

References (31)

1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
2. Book SA. Essentials of statistics. In: Arthur AA, Rogers J, Bradley JW, eds. Testing Statistical Hypotheses. New York: McGraw-Hill; 1978:117-122.
3. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
4. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
5. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican openangle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47:S77-S89.
6. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;131:631-635.
7. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121:453-457.
8. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132-135.
9. Konstas AGP, Papapanos P, Tersis I, et al. Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol/dorzolamide fixed combination. Ophthalmology. 2003;110:1357-1360.
10. Dubiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2002;45:S353-S360.
11. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
12. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
13. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
14. Konstas AGP, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262-266.
15. Alm A, Schoenfelder J, McDermott, J. A 5-year, multicenter, openlabel, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122:957-965.
16. Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004;122:1680-1685.
17. Schumer R, Camras C, Madahl A. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47:S219.
18. Stewart WC. How the new prostaglandins stack up: a look at what clinical studies reveal about travoprost and bimatoprost in relation to latanoprost. Rev Ophthalmol. 2002;9:58.
19. Bayer A, Weiler W, Oeverhaus U, et al. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004;20:470-478.
20. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82-87.
21. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51-55.
22. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176-181.
23. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:274-279.
24. Konstas AG, Hollo G, Astakhov YS, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol. 2004;122:29-33.
25. Grant WM, Burke JF. Why do some people go blind from glaucoma? Ophthalmology. 1982;89:991-998.
26. Kolker AE. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc. 1977;75:539.
27. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
28. Stewart WC. Clinical Practice of Glaucoma. Thorofare, NJ: SLACK, Inc., 1990.
29. Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol. 2004;14:407-415.
30. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2004;20:383-392.
31. Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol. 2003;13:21-29.